Due to the widespread acceptance of tumor-agnostic approaches in precision medicine, there is currently significant interest in investigating whether anti-HER2 therapies can be applied to other types of cancer, including biliary tract cancer (BTC). This evidence concerns the gene ERBB2 and biliary tract cancer.